Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — Q3 2025 Earnings Presentation
24 slides from Jazz Pharmaceuticals's earnings presentation, Nov 5, 2025
Slide 1: 2025 Third Quarter Financial Results
November 5, 2025 2025 Third Quarter Financial Results Innovating to Transform the Lives of Patients and Their Families Markella EPIDIOLEX® patient diagnosed with Dravet syndrome November 5, 2025
Slide 2: Caution Concerning Forward-Looking Statements
Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company’s growth prospects and future financial and operating results, in
Slide 3: Non-GAAP Financial Measures
Transforming Lives. Redefining Possibilities. Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with U.S. GAAP the Company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this present
Slide 4: Introduction and Overview
Introduction and Overview Renee Gala President and Chief Executive Officer 4 November 5, 2025
Slide 5: Strong 2025 Execution and Continued Focus on Growth
Strong 2025 Execution and Continued Focus on Growth COMMERCIAL PIPELINE FINANCIAL Highest ever quarterly revenue reflects Key opportunities across pipeline Disciplined capital allocation enables continued execution investment in growth Sleep1: Zanidatamab: Updated FY25 guidance3 ranges: • Xywav® rev
Slide 6: Commercial Performance
Commercial Performance Sam Pearce Executive Vice President and Chief Commercial Officer 6 November 5, 2025
Slide 7: Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity
Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity Sleep2 therapeutic area: • Total sleep2 revenue of $520 million in 3Q25 IH Narcolepsy 15,225 15,675 14,600 14,150 4,950 • Increase of ~450 net patients QoQ; Xywav revenue grew 11% YoY 13,625 4,225 4,625 3,900 3,550 • JazzCares servi
Slide 8: Epidiolex: Durable Growth with High Unmet Need
Epidiolex: Durable Growth with High Unmet Need Revenue: +20% YoY Epidiolex is the #1 branded epilepsy treatment1 • Poised to reach blockbuster status in 2025 $303 Growth opportunities: • Further data generation, including beyond-seizure benefits from the Net product sales ($ in millions) $252 EpiCom
Slide 9: Rylaze: Critical Component of U.S. ALL/LBL Treatment Protocols
Rely on Rylaze: Critical Component of U.S. ALL/LBL Treatment Protocols Revenue: +1% YoY Only therapy available to patients in the U.S. who have a hypersensitivity reaction to E. coli-derived asparaginase $99 $100 Continued focus on: Net product sales ($ in millions) • Increased use in adolescent/you
Slide 10: Zepzelca: Opportunity to Redefine 1L SCLC Treatment Paradigm
PIPELINE Zepzelca: Opportunity to Redefine 1L SCLC Treatment Paradigm Revenue: -8% YoY FDA approved Zepzelca in combination with Tecentriq combination as first-line maintenance therapy for ES-SCLC $86 • Opportunity to redefine the treatment paradigm in 1L maintenance $79 • Included in NCCN Guideline
Slide 11: Modeyso: Strong Initial Uptake and Early Launch Success
Modeyso: Strong Initial Uptake and Early Launch Success 1 2 3 Disease State Awareness Branded Campaign Launch Launch Exceeding Expectations & Education Strong HCP engagement CNS WHO Grade 4 glioma1 Driving comprehensive The most aggressive form launch plan of glioma Invariably lethal with rapid mort
Slide 12: Research & Development
Research & Development Robert Iannone, M.D., M.S.C.E. Executive Vice President, Global Head of Research & Development, Chief Medical Officer 12 November 5, 2025
Slide 13: Key Pipeline Programs
Key Pipeline Programs Key Clinical Programs PHASE 1 PHASE 2 PHASE 3 PHASE 4 / REGULATORY Recent / Upcoming Milestones Phase 3 1L GEA (pivotal) Phase 3 top-line PFS readout expected 4Q25 Phase 3 1L BTC Phase 3 confirmatory trial in 1L BTC ongoing Phase 3 BC in patients who have progressed on previous
Slide 14: HERIZON-GEA-01 Trial Top-Line Readout Expected 4Q25
HERIZON-GEA-01 Trial Top-Line Readout Expected 4Q25 Study Overview: • Primary Endpoints: Progression-free survival (PFS) and overall survival (OS) • Both primary endpoints will now include full 920 intent-to-treat patient population • Patients with locally advanced, recurrent or metastatic HER2-posi
Slide 15: Financial Performance
Financial Performance Phil Johnson Executive Vice President, Chief Financial Officer 15 November 5, 2025
Slide 16: Focus on 2025 Commercial Execution and Disciplined Investment
Focus on 2025 Commercial Execution and Disciplined Investment 3Q25 Total Revenues 3Q25 Non-GAAP ANI2,3 and EPS2,3 Continue to grow and diversify commercial portfolio: +7% YoY ANI2,4 EPS2,4 • Xywav revenues of $431M in 3Q25, 11% growth YoY • Epidiolex revenues of $303M in 3Q25, $1,126M 20% growth YoY
Slide 17: 2025 Non-GAAP Adjusted Guidance; Investing to Drive Growth
2025 Non-GAAP Adjusted Guidance ; Investing to Drive Growth 1 Total Revenues SG&A2 R&D2 ANI2,3 • Narrowed 2025 total revenue • Includes: $324M related to litigation • Includes: R&D costs associated with • Includes: $948M in acquired IPR&D guidance range settlement expenses and dordaviprone as well a
Slide 18: Closing
Closing Renee Gala President and Chief Executive Officer 18 November 5, 2025
Slide 19: Well-Positioned to Deliver Meaningful Shareholder Value
Well-Positioned to Deliver Meaningful Shareholder Value COMMERCIAL EXECUTION PIPELINE CATALYSTS Meaningful growth opportunity in IH Zanidatamab Phase 3 1L GEA top-line PFS data expected 4Q25 Poised to reach blockbuster status Multiple registrational trials active and enrolling patients Operational O
Slide 20: Appendix
Appendix 0 Jazz Pharmaceuticals.
Slide 21: Glossary
Glossary Acronym Definition Acronym Definition 1L First-line HCP Healthcare provider 1LM First-line maintenance HER2 Human epidermal growth factor receptor 2 2L Second-line HSR Hypersensitivity reaction AG Authorized generic IH Idiopathic hypersomnia ALL / LBL Acute lymphoblastic leukaemia / lymphob
Slide 22: Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information 1 Three Months Ended September 30, In thousands, except per share amounts 2025 2024 (unaudited) Net Income Diluted EPS Net Income Diluted EPS GAAP reported2 $251,412 $4.08 $215,055 $3.42 Intangible asset amortization 168,368 2.73 157,4
Slide 23: Reconciliation of GAAP to Non-GAAP Adjusted 2025 Guidance as of November 5, 2025
Reconciliation of GAAP to Non-GAAP Adjusted 2025 Guidance as of 1 November 5, 2025 2025 Guidance 2025 Guidance In millions, except per share amounts In millions (unaudited) Net Income / Diluted EPS / (unaudited) SG&A R&D (Loss) (LPS) GAAP2 $(435) - $(315) $(7.10) - $(5.20) GAAP expenses $1,786 - $1,
Slide 24: Reconciliation of GAAP to Non-GAAP Adjusted 2025 Guidance as of August 5, 2025
Reconciliation of GAAP to Non-GAAP Adjusted 2025 Guidance as of 1 August 5, 2025 2025 Guidance 2025 Guidance In millions, except per share amounts In millions (unaudited) Net Income / Diluted EPS / (unaudited) SG&A R&D (Loss) (LPS) GAAP $(565) - $(450) $(9.25) - $(7.50) GAAP expenses $1,620 - $1,693